Kiwi Biosciences (YC S21)

📍 Cambridge, United States🗓 Founded 2020👥 8 employees💰 Last funded Sep 2022
Biotechnology🌐 kiwibiosciences.com
Website LinkedIn
Kiwi Bio develops enzymes to make food painless for the 40M Americans who suffer from Irritable Bowel Syndrome (IBS). Our first patent-pending product, FODZYME, breaks down digestive triggers in garlic, onion, wheat, banana, and more so folks with gut disorders can enjoy their favorite foods.
1
Total investors
1
Early stage
0
Mid stage
0
Late stage
2020
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in Kiwi Biosciences (YC S21)?
Kiwi Biosciences (YC S21) has 1 investors on record on gritt.io, including 1 early-stage backers.
When did Kiwi Biosciences (YC S21) last raise funding?
The most recent investment in Kiwi Biosciences (YC S21) recorded on gritt.io was in September 2022.
When was Kiwi Biosciences (YC S21) founded?
Kiwi Biosciences (YC S21) was founded in 2020.
What industry is Kiwi Biosciences (YC S21) in?
Kiwi Biosciences (YC S21) operates in Biotechnology. Find similar Biotechnology investors on gritt.io.
Where is Kiwi Biosciences (YC S21) based?
Kiwi Biosciences (YC S21) is headquartered in Cambridge, United States.